{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:20:20Z","timestamp":1783527620537,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ZonMw NL","award":["852004019"],"award-info":[{"award-number":["852004019"]}]},{"name":"Ministry of Health, Welfare and Sport","award":["Ministry of Health, Welfare and Sport (Ministerie van Volksgezondheid, Welzijn en Sport)"],"award-info":[{"award-number":["Ministry of Health, Welfare and Sport (Ministerie van Volksgezondheid, Welzijn en Sport)"]}]},{"DOI":"10.13039\/501100007953","name":"Koninklijk Nederlands Genootschap voor Fysiotherapie","doi-asserted-by":"publisher","award":["Koninklijk Nederlands Genootschap voor Fysiotherapie"],"award-info":[{"award-number":["Koninklijk Nederlands Genootschap voor Fysiotherapie"]}],"id":[{"id":"10.13039\/501100007953","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022115","name":"Dutch Arthritis Association","doi-asserted-by":"publisher","award":["Dutch Arthritis Association"],"award-info":[{"award-number":["Dutch Arthritis Association"]}],"id":[{"id":"10.13039\/501100022115","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>To evaluate the cost-utility of long-term, personalized, exercise therapy as compared to usual care in people with axial spondyloarthritis (axSpA) and severe functional limitations. A comprehensive economic evaluation was conducted from a societal perspective alongside a randomized controlled trial involving 214 participants (110 individuals assigned to the intervention group and 104 to the usual care group), with a one-year follow-up. Cost assessments encompassed both medical and non-medical costs recorded by participants and healthcare providers. Quality Adjusted Life Years (QALYs) were calculated using the EuroQol-5 Dimensions -5 Levels (EQ-5D-5L) and EuroQol Visual Analogue Scale (EQ-VAS). Costs and QALY differences were analysed using standard unequal variance t-tests according to the intention-to-treat principle and cost-effectiveness acceptability curves. In the intervention group, 93% of the participants used the intervention with an average of 41 (standard deviation, SD 15) sessions, with the mean direct costs of the intervention being \u20ac1515 (SD 724) per participant. The total mean physiotherapy costs were \u20ac1967 (SD 801) in the intervention and \u20ac514 (SD 792) in the control group, respectively. Although not statistically significant, the total societal costs also favoured the usual care group after 52-weeks, showing a difference of \u20ac657 (95% confidence interval (CI) \u20ac-3748 to \u20ac5060). QALYs were slightly and non-significantly favouring the intervention group, with a difference of 0.02 based on the EQ-5D-5\u00a0L (95% CI\u2009\u2212\u20090.04 to 0.09) and 0.00 according to the EQ-VAS (95% CI -0.04 to 0.04). At a willingness-to-pay threshold of \u20ac50,000 per QALY, the intervention had a 57% likelihood of being considered the cost-effective strategy. The higher intervention costs of the long-term exercise therapy intervention were negated by savings on other healthcare and non-healthcare costs and by improved QALYs. As a result, we found no clear economic preference: long-term exercise therapy need not be withheld for economic reasons from people with axSpA and severe functional limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration number<\/jats:title>\n                    <jats:p>Netherlands Trial Register NL-OMON52399, included in the International Clinical Trial Registry Platform (ICTRP) (https:\/\/trialsearch.who.int\/Trial2.aspx? TrialID=NL-OMON52399).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00296-026-06160-x","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:14:43Z","timestamp":1780665283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-utility of long-term exercise therapy in people with axial spondyloarthritis and severe functional limitations: a randomized, controlled trial"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2998-4256","authenticated-orcid":false,"given":"Maria. A. T.","family":"van Wissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8560-4687","authenticated-orcid":false,"given":"Salima F. E.","family":"van Weely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4352-2824","authenticated-orcid":false,"given":"Cornelia. H. M.","family":"van den Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-3859","authenticated-orcid":false,"given":"Theodora P. M.","family":"Vliet Vlieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3235-7800","authenticated-orcid":false,"given":"Max M. H.","family":"Teuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-2429","authenticated-orcid":false,"given":"Wilfred. F.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6833-3157","authenticated-orcid":false,"given":"Eline A. M.","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4006-3762","authenticated-orcid":false,"given":"Dirkjan","family":"van Schaardenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-7407","authenticated-orcid":false,"given":"Floris","family":"van Gaalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8850-8578","authenticated-orcid":false,"given":"Johanna P. L.","family":"Spoorenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8477-0683","authenticated-orcid":false,"given":"Astrid M.","family":"van Tubergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6106-3385","authenticated-orcid":false,"given":"Maaike G. J.","family":"Gademan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-0135","authenticated-orcid":false,"given":"Wilbert B.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"5","key":"6160_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.2024.20917","volume":"333","author":"M Bittar","year":"2025","unstructured":"Bittar M, Deodhar A (2025) Axial Spondyloarthritis : A Review. (JAMA 333(5):408\u2013420. https:\/\/doi.org\/10.1001\/jama.2024.20917","journal-title":"JAMA"},{"issue":"10089","key":"6160_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(16)31591-4","journal-title":"Lancet"},{"issue":"10","key":"6160_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41584-025-01286-x","volume":"21","author":"JD Reveille","year":"2025","unstructured":"Reveille JD, Eder L, Ziade N, Sampaio-Barros PD, Kim TH, Akko\u00e7 N, Brown MA (2025) Global epidemiology of spondyloarthritis. Nat Rev Rheumatol 21(10):580\u2013598. https:\/\/doi.org\/10.1038\/s41584-025-01286-x","journal-title":"Nat Rev Rheumatol"},{"key":"6160_CR4","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00296-024-05615-3","volume":"44","author":"O Zimba","year":"2024","unstructured":"Zimba O, Kocyigit BF, Korkosz M (2024) Diagnosis, monitoring, and management of axial spondyloarthritis. Rheumatol Int 44:1395\u20131407. https:\/\/doi.org\/10.1007\/s00296-024-05615-3","journal-title":"Rheumatol Int"},{"issue":"1","key":"6160_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewe RBM, Van den Bosch FE, Boteva B, Bremander A, Carron P, Ciurea A, van Gaalen FA, Geher P, Gensler L, Hermann J, de Hooge M, Husakova M, Kiltz U, Lopez-Medina C, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compan V, Nissen MJ, Pimentel-Santos FM, Poddubnyy D, Proft F, Rudwaleit M, Telkman M, Zhao SS, Ziade N, van der Heijde D (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82(1):19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"key":"6160_CR6","unstructured":"NICE (2018) Spondyloarthritis Quality Standard. https:\/\/www.nice.org.uk\/guidance\/qs170\/resources\/spondyloarthritis-pdf-75545654188741. Accessed April 26, 2026"},{"issue":"1","key":"6160_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/ard-2022-223297","volume":"82","author":"A Ortolan","year":"2023","unstructured":"Ortolan A, Webers C, Sepriano A, Falzon L, Baraliakos X, Landewe RB, Ramiro S, van der Heijde D, Nikiphorou E (2023) Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis 82(1):142\u2013152. https:\/\/doi.org\/10.1136\/ard-2022-223297","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"6160_CR8","doi-asserted-by":"publisher","first-page":"Cd011321","DOI":"10.1002\/14651858.CD011321.pub2","volume":"10","author":"JP Regnaux","year":"2019","unstructured":"Regnaux JP, Davergne T, Palazzo C, Roren A, Rannou F, Boutron I, Lefevre-Colau MM (2019) Exercise programmes for ankylosing spondylitis. Cochrane Database Syst Rev 10(10):Cd011321. https:\/\/doi.org\/10.1002\/14651858.CD011321.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"6160_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00296-014-2965-7","volume":"34","author":"T O\u2019Dwyer","year":"2014","unstructured":"O\u2019Dwyer T, O\u2019Shea F, Wilson F (2014) Exercise therapy for spondyloarthritis: a systematic review. Rheumatol Int 34(7):887\u2013902. https:\/\/doi.org\/10.1007\/s00296-014-2965-7","journal-title":"Rheumatol Int"},{"key":"6160_CR10","doi-asserted-by":"publisher","unstructured":"Gwinnutt JM, Wieczorek M, Cavalli G, Balanescu A, Bischoff-Ferrari HA, Boonen A, de Souza S, de Thurah A, Dorner TE, Moe RH, Putrik P, Rodriguez-Carrio J, Silva-Fernandez L, Stamm T, Walker-Bone K, Welling J, Zlatkovic-Svenda MI, Guillemin F, Verstappen SMM (2022) Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open 8(1). https:\/\/doi.org\/10.1136\/rmdopen-2021-002168","DOI":"10.1136\/rmdopen-2021-002168"},{"issue":"1","key":"6160_CR11","doi-asserted-by":"publisher","first-page":"e1933","DOI":"10.1002\/pri.1933","volume":"27","author":"MAT van Wissen","year":"2022","unstructured":"van Wissen MAT, Teuwen MMH, van den Ende CHM, Vliet Vlieland TPM, den Broeder AA, van den Hout WB, Peter WF, van Schaardenburg D, van Tubergen AM, Gademan MGJ, van Weely SFE (2022) Effectiveness and cost-effectiveness of longstanding exercise therapy versus usual care in patients with axial spondyloarthritis or rheumatoid arthritis and severe limitations: The protocols of two parallel randomized controlled trials. Physiother Res Int Jan 27(1):e1933. https:\/\/doi.org\/10.1002\/pri.1933","journal-title":"Physiother Res Int Jan"},{"issue":"4","key":"6160_CR12","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/rheumatology\/keae323","volume":"64","author":"MAT van Wissen","year":"2025","unstructured":"van Wissen MAT, van den Ende CHM, Gademan MGJ, Teuwen MMH, Peter WF, Mahler EAM, van Schaardenburg D, van Gaalen FA, Spoorenberg A, van den Hout WB, van Tubergen AM, Vliet Vlieland TPM, van Weely SFE (2025) One-year effectiveness of long-term exercise therapy in people with axial spondyloarthritis and severe functional limitations. Rheumatology (Oxford) 64(4):1817\u20131825. https:\/\/doi.org\/10.1093\/rheumatology\/keae323","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"6160_CR13","first-page":"264","volume":"21","author":"C Bakker","year":"1994","unstructured":"Bakker C, Hidding A, van der Linden S, van Doorslaer E (1994) Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial. J Rheumatol 21(2):264\u2013268","journal-title":"J Rheumatol"},{"issue":"5","key":"6160_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/art.10658","volume":"47","author":"A Van Tubergen","year":"2002","unstructured":"Van Tubergen A, Boonen A, Landewe R, Rutten-Van Molken M, Van Der Heijde D, Hidding A, Van Der Linden S (2002) Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 47(5):459\u2013467. https:\/\/doi.org\/10.1002\/art.10658","journal-title":"Arthritis Rheum"},{"issue":"2","key":"6160_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/03009742.2024.2392360","volume":"54","author":"M Teuwen","year":"2025","unstructured":"Teuwen M, van Weely S, van den Ende C, van Wissen M, Vliet Vlieland T, Peter WF, den Broeder AA, van Schaardenburg D, Gademan M, van den Hout WB (2025) Cost-utility analysis of longstanding exercise therapy versus usual care in people with rheumatoid arthritis and severe functional limitations. Scand J Rheumatol 54(2):87\u201397. https:\/\/doi.org\/10.1080\/03009742.2024.2392360","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"6160_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/jcsm.12091","volume":"7","author":"NM de Vries","year":"2016","unstructured":"de Vries NM, Staal JB, van der Wees PJ, Adang EM, Akkermans R, Olde Rikkert MG, Nijhuis-van der Sanden MW (2016) Patient-centred physical therapy is (cost-) effective in increasing physical activity and reducing frailty in older adults with mobility problems: a randomized controlled trial with 6 months follow-up. J Cachexia Sarcopenia Muscle 7(4):422\u2013435. https:\/\/doi.org\/10.1002\/jcsm.12091","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"11","key":"6160_CR17","doi-asserted-by":"publisher","first-page":"e0187477","DOI":"10.1371\/journal.pone.0187477","volume":"12","author":"TA Kanters","year":"2017","unstructured":"Kanters TA, Bouwmans CAM, van der Linden N, Tan SS, Hakkaart-van Roijen L (2017) Update of the Dutch manual for costing studies in health care. PLoS ONE 12(11):e0187477. https:\/\/doi.org\/10.1371\/journal.pone.0187477","journal-title":"PLoS ONE"},{"key":"6160_CR18","unstructured":"Hakkaart-van Roijen L, VdLN, Bouwmans CAM, Kanters TA, Tan SS (2015) Costing manual: Methodology of costing research and reference prices for economic evaluations in healthcare [in Dutch: Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg]"},{"key":"6160_CR19","doi-asserted-by":"publisher","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S, Force CIGRPT (2022) Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ 376:e067975. https:\/\/doi.org\/10.1136\/bmj-2021-067975","journal-title":"BMJ"},{"key":"6160_CR20","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group C (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340:c332. https:\/\/doi.org\/10.1136\/bmj.c332","journal-title":"BMJ"},{"key":"6160_CR21","unstructured":"(2016) Zelf gerapporteerde medische consumptie, gezondheid en leefstijl https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/03799\/table"},{"issue":"8","key":"6160_CR22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/rheumatology\/34.8.793","volume":"34","author":"A Calin","year":"1995","unstructured":"Calin A, Jones SD, Garrett SL, Kennedy LG (1995) Bath Ankylosing Spondylitis Functional Index. Br J Rheumatol 34(8):793\u2013794. https:\/\/doi.org\/10.1093\/rheumatology\/34.8.793","journal-title":"Br J Rheumatol"},{"issue":"3","key":"6160_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.10397","volume":"47","author":"A Van Tubergen","year":"2002","unstructured":"Van Tubergen A, Debats I, Ryser L, Londo\u00f1o J, Burgos-Vargas R, Cardiel MH, Landew\u00e9 R, Stucki G, Van Der Heijde D (2002) Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthritis Rheum 47(3):242\u2013248. https:\/\/doi.org\/10.1002\/art.10397","journal-title":"Arthritis Rheum"},{"issue":"3","key":"6160_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group (1990) EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy 16(3):199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9","journal-title":"Health Policy"},{"issue":"4","key":"6160_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","volume":"19","author":"MM Versteegh","year":"2016","unstructured":"Versteegh MM, Vermeulen KM, Evers SMAA, de Wit GA, Prenger R, Stolk EA (2016) Dutch Tariff for the Five-Level Version of EQ-5D. Value Health 19(4):343\u2013352. https:\/\/doi.org\/10.1016\/j.jval.2016.01.003","journal-title":"Value Health"},{"issue":"2","key":"6160_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1017\/s0266462300009648","volume":"12","author":"AM Stiggelbout","year":"1996","unstructured":"Stiggelbout AM, Eijkemans MJ, Kiebert GM, Kievit J, Leer JW, De Haes HJ (1996) The \u2018utility\u2019 of the visual analog scale in medical decision making and technology assessment. Is it an alternative to the time trade-off? Int J Technol Assess Health Care 12(2):291\u2013298. https:\/\/doi.org\/10.1017\/s0266462300009648","journal-title":"Int J Technol Assess Health Care"},{"issue":"8","key":"6160_CR27","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.3899\/jrheum.110404","volume":"38","author":"MJ Harrison","year":"2011","unstructured":"Harrison MJ, Bansback NJ, Marra CA, Drummond M, Tugwell PS, Boonen A (2011) Valuing health for clinical and economic decisions: directions relevant for rheumatologists. J Rheumatol 38(8):1770\u20131775. https:\/\/doi.org\/10.3899\/jrheum.110404","journal-title":"J Rheumatol"},{"issue":"6","key":"6160_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jval.2015.05.009","volume":"18","author":"C Bouwmans","year":"2015","unstructured":"Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Hakkaart-van Roijen L (2015) The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses. Value Health 18(6):753\u2013758. https:\/\/doi.org\/10.1016\/j.jval.2015.05.009","journal-title":"Value Health"},{"key":"6160_CR29","unstructured":"Bouwmans CH, Krol M, Severens J, Brouwer W (2013) Manual of the iMTA medical consumption questionnaire (iMCQ). https:\/\/iMTA Medical Consumption Questionnaire - iMTA (accessed April 27, 2026)"},{"issue":"2","key":"6160_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0167-6296(94)00044-5","volume":"14","author":"MA Koopmanschap","year":"1995","unstructured":"Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Econ 14(2):171\u2013189. https:\/\/doi.org\/10.1016\/0167-6296(94)00044-5","journal-title":"J Health Econ"},{"key":"6160_CR31","doi-asserted-by":"publisher","unstructured":"van den Hout WB (2010) The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 69 Suppl 1i89\u201391. https:\/\/doi.org\/10.1136\/ard.2009.117150","DOI":"10.1136\/ard.2009.117150"},{"key":"6160_CR32","doi-asserted-by":"publisher","first-page":"b2393","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JA Sterne","year":"2009","unstructured":"Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338:b2393. https:\/\/doi.org\/10.1136\/bmj.b2393","journal-title":"BMJ"},{"key":"6160_CR33","doi-asserted-by":"publisher","unstructured":"Brand J, van Buuren S, le Cessie S, van den Hout W (2019) Combining multiple imputation and bootstrap in the analysis of cost-effectiveness trial data. Stat Med. 2019;38(2):210\u2013220. https:\/\/doi.org\/10.1002\/sim.7956","DOI":"10.1002\/sim.7956"},{"issue":"6","key":"6160_CR34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1191\/0962280202sm304ra","volume":"11","author":"BJ O\u2019Brien","year":"2002","unstructured":"O\u2019Brien BJ, Briggs AH (2002) Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res 11(6):455\u2013468. https:\/\/doi.org\/10.1191\/0962280202sm304ra","journal-title":"Stat Methods Med Res"},{"key":"6160_CR35","unstructured":"Zwaap JKS, Van der Meijden C, Staal P, van der Heiden L (2015) Cost-effectiveness in practice (in Dutch) https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2015\/06\/16\/cost-effectiveness-in-practice. Accessed 20\u2009\u2013\u200906, 2023"},{"key":"6160_CR36","doi-asserted-by":"publisher","unstructured":"Butink MHP, Webers C, Verstappen SMM, Falzon L, Betteridge N, Wiek D, Woolf AD, Stamm TA, Burmester GR, Bijlsma JWJ, Christensen R, Boonen A (2023) Non-pharmacological interventions to promote work participation in people with rheumatic and musculoskeletal diseases: a systematic review and meta-analysis from the EULAR taskforce on healthy and sustainable work participation. RMD Open 9(1). https:\/\/doi.org\/10.1136\/rmdopen-2022-002903","DOI":"10.1136\/rmdopen-2022-002903"},{"issue":"1","key":"6160_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00296-025-06016-w","volume":"46","author":"NF Bakker","year":"2025","unstructured":"Bakker NF, Knoop J, van den Hout WB, Hutting N, Engels JA, Staal JB, van der Leeden M, Boonen A, Willemze A, Nurmohamed MT, Vliet Vlieland TPM, Gademan MGJ, van Weely SFE (2025) Effectiveness and cost-effectiveness of a multimodal, physiotherapist-led, vocational intervention for people with rheumatoid arthritis or axial spondyloarthritis and a reduced work ability: a randomized, controlled trial (2025). Rheumatol Int 46(1):11. https:\/\/doi.org\/10.1007\/s00296-025-06016-w","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06160-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06160-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06160-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:39:18Z","timestamp":1783525158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06160-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["6160"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06160-x","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.A.T van Wissen, S. F.E. van Weely, C.H.M. van den Ende, T.P.M. Vliet Vlieland, M.M.H Teuwen, W.F. Peter, E.A.M. Mahler, D. van Schaardenburg, J.P.L. Spoorenberg, M. G.J. Gademan, and W.B. van den Hout declare that they have no known conflicts of interest. Astrid M. van Tubergen received speaker fees from Pfizer and Novartis; consulting fees from Abbvie, Novartis, Johnsson and Johnson, and UCB; and unrestricted research grants from Abbvie, UCB, and Novartis. F. van Gaalen is member of the ASAS Executive Committee and ASAS treasurer and received grants from Stichting Vrienden van Sole Mio and Stichting ASAS and fees\/contracts from AbbVie, Novartis, UCB, Alfasigma, Johnson&Johnson, Lilly, Merck, and Pfizer with all payments made to employer (LUMC, full time contract).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Medical Ethical Review Board Leiden-Delft-Den Haag on July 11, 2019 (METC-LDD, NL70093.058.19,\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This report was not prearchived in a local repository.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prearchiving note"}},{"value":"The results of this economic analysis have not been previously presented as an abstract.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous publication"}}],"article-number":"134"}}